Dimethyl fumarate and its esters: a drug with broad clinical utility?
journal contribution
posted on 2023-05-22, 23:59authored byKourakis, S, Timpani, CA, de Haan, JB, Nuri GuvenNuri Guven, Fischer, D, Rybalka, E
Fumaric acid esters (FAEs) are small molecules with anti‐oxidative, anti‐inflammatory and immune‐modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing‐Remitting Multiple Sclerosis (RRMS). Psoriasis and RRMS share an immune‐mediated aetiology, driven by severe inflammation and oxidative stress. DMF, as well as monomethyl fumarate and diroximel fumarate, are commonly prescribed first‐line agents with favourable safety and efficacy profiles. The potential benefits of FAEs against other diseases that appear pathogenically different but share the pathologies of oxidative stress and inflammation are currently investigated.
History
Publication title
Pharmaceuticals
Volume
13
Issue
10
Pagination
1-15
ISSN
1424-8247
Department/School
School of Pharmacy and Pharmacology
Publisher
MDPI AG
Place of publication
Switzerland
Repository Status
Restricted
Socio-economic Objectives
Clinical health not elsewhere classified; Other health not elsewhere classified